Overview

Metformin as Added on Therapy in Patients With Ulcerative Colitis

Status:
Not yet recruiting
Trial end date:
2027-04-01
Target enrollment:
Participant gender:
Summary
Ulcerative colitis (UC) is a chronic inflammatory bowel disease that is marked by increased intestinal motility and bloody diarrhea. The clinical value of existing therapeutic strategies of UC, including glucocorticoids, anti-tumor necrosis factor α (TNF-α), mesalamine, and thiopurines is still limited. Therefore, the discovery of new therapeutic approaches is essential to improve the effectiveness of the treatment.Adenosine monophosphate (AMP)-activated protein kinase (AMPK) is a conserved fuel-sensing enzyme that plays an important role in the regulation of cellular metabolism where it increases glucose and fatty acids uptake and activates the oxidation process to improve the cellular energy utilization
Phase:
Phase 2
Details
Lead Sponsor:
Tanta University
Treatments:
Metformin